Products

Cefditor Tablets are indicated in the treatment of mild to moderate infections in adults and adolescents (12 years of age or older), which are caused by susceptible strains of the designated microorganisms in the conditions listed below: Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) caused by Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae (including beta-lactamase-producing strains),Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including beta-lactamase-producing strains). Community-Acquired Pneumonia (CAP) caused by Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including betalactamase- producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcusaureus (including beta-lactamase-producing strains) or Streptococcus pyogenes.

Adults: ABECB: 400mg bid for 10 days. Pharyngitis/Tonsillitis/SSSI: 200mg bid for 10 days. CAP: 400mg bid for 14 days. Take with meals. Pediatrics: 12 yrs: ABECB: 400mg bid for 10 days. Pharyngitis/Tonsillitis/SSSI: 200mg bid for 10 days. CAP: 400mg bid for 14 days.

Contraindicated in patients hypersensitive to drug or other cephalosporins. Also contraindicated in patients with carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency. Because cefditoren tablets contain sodium caseinate, a milk protein, don't give to patients hypersensitive to milk protein (as distinct from those with lactose intolerance).